您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
Invivo anti-mouse CD25 Recombinant mAb

Invivo anti-mouse CD25 Recombinant mAb

货号: S0B0873
价格: 900
规格: 1mg
介绍: -
其他: -
产品规格
  • 宿主来源

    Rat
  • 抗原名称

    CD25
  • Accession

    P01590
  • 克隆号

    S-R441
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    IgG2a,k
  • 同型对照

    S0B0932
  • 应用

    in vivo regulatory T cell depletion, FCM
  • 反应种属 ?

    Ms
  • 纯化方式

    Protein G
  • 浓度

    5 mg/ml
  • 纯度

    >95% Determined by SDS-PAGE
  • 内毒素含量

    <2EU/mg
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS pH7.4, containing no preservative

  • 储存条件

    2 to 8 °C for 2 weeks under sterile conditions;

    -20 °C for 3 months under sterile conditions; 

    -80 °C for 24 months under sterile conditions.

    Please avoid repeated freeze-thaw cycles.

  • 稀释度

背景介绍
  • This antibody recognizes the same epitope as clone PC61. CD25, also known as the alpha chain of the interleukin-2 receptor (IL-2Rα), plays a significant role in the immune system. CD25 is a characteristic marker for Tregs, a subset of T cells that help suppress immune responses, thereby maintaining immune system homeostasis and self-tolerance. Tregs are particularly important in preventing autoimmune diseases and are also involved in the immune response to tumors. The expression of CD25 increases upon activation of T cells, making it a useful marker for identifying activated immune cells. High levels of CD25 expression are found in various hematological malignancies and are associated with Tregs within the tumor microenvironment. Targeting CD25 has been explored as a potential therapeutic strategy in cancer treatment, particularly in redirecting the immune response against tumors. There are monoclonal antibodies and other agents that target CD25, such as Daclizumab, which has been used in the treatment of multiple sclerosis and as an immunosuppressive agent in organ transplantation.